Pharma major, Lupin Limited, has partnered with a global healthcare leader, Eli Lilly, to commercialize and distribute Cialis, an oral PDE5 inhibitor, in India –for the treatment of erectile dysfunction (ED) in adult males.
The partnership provides exclusive licensing agreement to Lupin with rights to market, promote and distribute Lilly’s Erectile Dysfunction (ED) product, Cialis, through its specialty field force. Lilly will be responsible for manufacturing and importing the product, Lupin said in an official statement.
The Cialis tablet is currently being marketed in over 1000 countries and is available in 10 mg and 20 mg strength.
The President (India Region Formulations) of Lupin, Rajeev Sibal, said: “Lupin’s entry into the fast growth PDE-5 inhibitors market will address the unmet medical need in ED space in India. The launch demonstrates Lupin’s commitment to grow its brand franchise in India and bring meaningful products to patients in the country.”
The PDE-5 market in India is valued at around Rs 390 crore, out of which Tadalafil contributes around 23 per cent. Lupin says the market size has doubled since 2012 and is growing annually at 15 per cent.
As per a study, 52 per cent men in India between 40 to 70 years suffer from erectile dysfunction, Bureaucracy Today has learnt. ED causes depression, low self-esteem and affects the quality of life.
The Managing Director of Eli Lilly and Company (India), Edgard Olaizola, said: “Today, erectile dysfunction is a significant medical condition affecting large number of Indian men. This partnership will help expand our reach to more patients. Lilly is committed to bringing innovative products to India.”